

#### **Outside Equity and Healthcare Firm Behavior**

Haizhen Lin, Indiana University Elizabeth Munnich, University of Louisville Michael R Richards, Baylor University Christopher M Whaley, RAND Xiaoxi Zhao, RAND

FTC Microeconomics Conference 2022



## Preview

- **Context**: Examining ASC behavior under 3 different external financial investment contexts
- PE investments mostly affect the financial engineering, rather than treatment style, of standalone ASCs
  - Charge more per case; crowd-in physician equity ownership
- PE acquisition of an ASC chain does not generate the same effects
- A looming IPO seems to encourage revenue maximization for the chain



## Motivation

- Raising capital for US businesses has shifted from public markets to private markets esp. private equity (PE) funds (Mauboussin and Callahan 2020; McKinsey & Co 2022)
- Views on the net effects of PE are mixed (Jensen 1986, 1988; Schleifer and Summers 1988; Davis et al. 2014, 2019; Argawal and Tambe 2016; Olsson and Tag 2017; Antoni et al. 2019)
- PE involvement in US healthcare is rapidly growing
  - Nearly \$800 billion in past 10 years (Scheffler, Alexander, and Godwin 2021)
  - Returns typically better than other PE investments (Bain & Co 2022)



## Motivation

- Growth of PE in healthcare is controversial
  - **Fundamental concern**: PE investors might change how healthcare firms and professionals provide care at odds with patients' interests
- Emerging literature primarily capturing hospitals, nursing homes, and physician practices
  - Braun et al. 2020, 2021a, 2021b; Gandhi et al. 2020; Cerullo et al. 2021, 2022; Gao et al. 2021; Gupta et al. 2021; Offodile et al. 2021; Singh et al. 2022
- Other industries less examined to date



## Our Contribution

- PE has long been investing in the ASC industry (Newitt 2022)
- Single existing study on PE involvement in ASCs Dov Brunch et al. (2022)
  - Subsample of Medicare data; only capturing short-run investment effects
  - Largely focused on care quality outcomes; no effects
- Using all-payer data, we examine investment, divestment, and an IPO
- Capture changes in payer mix, case mix, treatment intensity, list prices, and physician ownership stakes



- Care delivery is moving out
  - Nearly 1/2 of hospital revenues now come from outpatient care (Bannow 2019)
  - Shift is pronounced for surgical care accounts for 1/3 of all US spending (Muñoz, Muñoz, and Wise 2010)
- Two rival industries in outpatient surgical care
  - Ambulatory Surgery Centers (ASCs)
  - Hospital Outpatient Departments (HOPDs)







Free-Standing Ambulatory Surgery Center (ASC)





- ASCs tend to be for-profit, urban, and small (MedPAC 2019)
- Rapid expansion in 1990s 2000s
- ~\$30 billion industry
  - Medicare spends nearly \$5 billion on ASC-delivered per year (MedPAC 2019)



Munnich and Richards (2022)



- ASCs typically offer greater consumer convenience and lower service prices (Grisel et al. 2009; Munnich and Parente 2018; Aouad, Brown, and Whaley 2019; Sood and Whaley 2019)
- When ASCs enter, HOPDs have lower volumes and worse finances (Bian and Morrisey 2007; Courtemanche and Plotzke 2010; Carey, Burgess, and Young 2011; Koeing and Gu 2013; Hollenbeck et al. 2015)
- ASCs seem to place downward pressure on HOPD prices (Carey 2017; Whaley and Brown 2019; Baker, Bundorf, and Kessler 2019)
- PE and other investors have history of targeting the ASC industry (Newitt 2022)



#### **Research Question:**

Do outside equity investors change the behavior of ASCs and does the source of investment matter?



### Data

- CMS FOIA: ASC owners and timing of ownership see Munnich et al. (2021)
- PE owners among Florida ASCs
  - S&P Capital IQ Pro, Bloomberg Businessweek and Bloomberg Terminal, Factivia, SCD Platinum's M&A lists, SEC reports
- Florida AHCA outpatient surgery discharge records 2004 2019



## **Empirical Outline**

- Stacked diff-in-diff event studies for PE **investment** and **divestment** in standalone ASCs
- Standard diff-in-diff for PE acquisition of an ASC chain and eventual **IPO**



## Estimation Approach: PE Investment

- Focus on longstanding ASCs in FL markets
- Treated:
  - > 5 years of PE ownership
- Controls:
  - No direct or indirect PE involvement
  - Out-of-market relative to treated





## Estimation Approach: PE Investment

- Analytic data are at the firm-quarter-year level
- Implement a "stacked" DID event study
  - Quarters around PE investment: [-10, 23] for treated
  - For controls, randomly assign a placebo (anchor) date

$$Y_{at} = \sum_{\substack{j=-10\\ j\neq -4}}^{23} \delta_j \, \mathbb{I}[Treated_a \times (Time = j)] + \lambda_a + \gamma_t + \varepsilon_{at}$$



TABLE I Baselin	Summary Statistics for Analytic Sample	
	Treatment Group	Control Group
	<u>Mean</u>	<u>Mean</u>
Case Volume	1,468	989
Procedures Per Case	1.5	1.4
Total Charges Per Case	\$3,772	\$2,453
% Privato	52.2	33.7
% Traditional Medicare	34.8	53.3
Any Physician Owners	0.5	0.6
No. Physician Owners	2.2	1.7
Unique ASCs (N)	24	89







Avg. Number of Procedures Per Case



#### Avg. Complexity of Case





Singh et al. (2022) find higher charges and higher prices for physician practices







Approx. 20% decline over baseline level

% of Payer Mix Privately Insured



300% increase over baseline # owners





## Estimation Approach: PE Divestment

- Same style of "stacked" DID approach
- Focus on divestment among these same ASCs
  - Placebo (anchor) divestment date for control ASCs, just as before

$$Y_{at} = \sum_{\substack{j=-12\\ j\neq -4}}^{6} \theta_{j} \mathbb{I}[Treated_{a} \times (Time = j)] + \lambda_{a} + \gamma_{t} + \varepsilon_{at}$$



Any Physician Owners

No. Physician Owners







## Estimation Approach: PE Acquisition

- Surgery Partners founded in FL in 2004
- December 2009 wholly acquired by HIG Capital
- IPO September 2015



## Estimation Approach: PE Acquisition

- Traditional DID setup balanced panel of ASCs 2007 2017
- Treated: Surgery Partner ASCs prior to acquisition
- Controls: Out-of-market ASCs, never involved with PE

$$Y_{at} = \sum_{\substack{j=-12\\ j\neq -4}}^{30} \beta_j \, \mathbb{I}[Treated_a \times (Time = j)] + \lambda_a + \gamma_t + \varepsilon_{at}$$



TABLE III Summary Statistics for Analytic Sample 2007		Sample 2007-2009
	Treatment Group (Surgery Partners ASC Chain)	Control Group
	Mean	Mean
Case Volume	758	1,076
Procedures Per Case	2.5	1.6
Total Charges Per Case	\$7,616	\$3,046
% Private	59.8	39.6
% Traditional Medicare	22.0	47.7
No. Physician Owners	5.7	2.7
Unique ASCs (N)	8	66



















## Summary

- Clinical conduct of ASCs largely unfazed by PE
  - Physician decision-making and agency appear preserved
- Finances are affected: 1) higher list prices 2) more physician equity investments w/ coordinated divestments
  - Tying key human capital to firm (e.g., reputation and referrals)
  - Likely that intangible assets > tangible assets for ASCs
  - Contrasts with PE investments in other industries that shrink labor



## Summary

- Findings from PE acquisition of a chain often differ
  - Immediately before/after IPO seems influential
- Overall, results consistent with bespoke strategies for ASC investing
  - Not obviously harmful for patients so long as alternative providers available



## Thank you!

#### Email: michael\_richards@baylor.edu







